Name: Name:Merimepodib
Brand: Angene
SKU: AG002BQF
Rating: 90 (10 reviews)

Catalog Number:

AG002BQF

Chemical Name:

Merimepodib

CAS Number:

198821-22-6

Molecular Formula:

C23H24N4O6

Molecular Weight:

452.4599

MDL Number:

MFCD09837807

IUPAC Name:

[(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate

InChI:

InChI=1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)/t18-/m0/s1

InChI Key:

JBPUGFODGPKTDW-SFHVURJKSA-N

SMILES:

COc1cc(ccc1c1cnco1)NC(=O)Nc1cccc(c1)CNC(=O)O[C@@H]1COCC1

UNII:

2ZL2BA06FU

Complexity:

652

Compound Is Canonicalized:

Yes

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Defined Bond Stereocenter Count:

Exact Mass:

452.17g/mol

Formal Charge:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Isotope Atom Count:

Molecular Weight:

452.467g/mol

Monoisotopic Mass:

452.17g/mol

Rotatable Bond Count:

Topological Polar Surface Area:

124A^2

Undefined Atom Stereocenter Count:

Undefined Bond Stereocenter Count:

XLogP3:

2.1

Title	Journal
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.	Hepatology (Baltimore, Md.) 20091201
Ribavirin analogs.	Clinics in liver disease 20090801
Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.	Journal of hepatology 20071001
Understanding the degradation pathway of a poorly water-soluble drug formulated in PEG-400.	Journal of pharmaceutical and biomedical analysis 20070411
Low molecular weight indole fragments as IMPDH inhibitors.	Bioorganic & medicinal chemistry letters 20060501
A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.	Antiviral therapy 20050101
Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes.	Biochemical pharmacology 20040215
3-cyanoindole-based inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure-activity relationships.	Bioorganic & medicinal chemistry letters 20031020
Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl moiety.	Bioorganic & medicinal chemistry letters 20030616
The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.	Virology 20030605
Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity.	Journal of medicinal chemistry 20020523
VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent.	Journal of pharmaceutical sciences 20010501
Current and future therapies of hepatitis C.	Clinics in liver disease 20010501
New dermatological agents for the treatment of psoriasis.	Journal of medicinal chemistry 20010201
The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice.	Drugs under experimental and clinical research 20010101
Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon.	Antimicrobial agents and chemotherapy 20000401
Novel approaches to the treatment of hepatitis C virus infection.	Antiviral chemistry & chemotherapy 20000301